In line with increasing calls of transparency initiatives across European institutions, the European Medicines Agency (EMA) will on September 26th 2017 host its first public hearing on the regulatory of a drug, namely Valproate. According to the EMA website, the public hearing is intended to “increase transparency by opening up the scientific evaluation process” and “[give citizens] a voice in the evaluation of medicines.” This conference paper will present the preliminary results from a rhetorical analysis of the public hearing as a transparency measure. What kind transparency does a public hearing provide? How are citizens’ accounts positioned vis-à-vis expert testimonies? Does the public hearing achieve sufficient “hybridity” of its heterogeneous stakeholder group?